Ann: Imugene Advances VAXINIA MAST Trial to Next IV Cohorts, page-148

Rich&Poor,

That looks like the one. Timing is right. Remembering that IMU management have a much clearer view of the road ahead than we do. It was back in February that Yuman FONG told us that “we are seeing unequivocal evidence that CF33 is killing cancer cells in humans”. How long ago did LC first drop the phrase “obliterating solid tumors!” At least a year. Checkvax has been trials for TNBC has been running just short of 2 years now. So IMU has a ton of data to support CF33 in humans.

The paper IMU plans to submit for Peer Reviewed Publication in a prestigious journal befitting the science would likely include data from both the Checkvax trials and the MAST Vaccinia trials. This data and will also have Scans showing CF33 in action infecting and killing cancer cells. If that isn’t exciting enough it will also show scans of CF33 hunting down and killing distal tumors.

we could also expect to see, hard evidence of CF33 killing tumors from multiple different organs . Ie Kidney + Liver + Breast. That’s the headline that will hit front page news across the world.

In February Chairman Paul Hopper told us that plans for a NASDAQ Listing are well advanced, but would only happen with a major event or news to support the IMU listing. Fridays announcement just confirmed the major news announcements are now scheduled in. And thanks to Rich&Poors research we now know it’s 1-5 November 2023. It’s highly likely this will be the headline act at the Conference.

After watching LC speak many times over the years in video and in person , it’s clear to me she has been very good at clearly communicating the path forward. Always delivering what she has led us to expect. Approaching the Juky Biotech Summit and Shareholders Roadshow, We can expect a lot more “obliterating solid tumot” and “Unequivocal evidence” statements. Which management will back up with “data” and “science”.

This Tuesday morning we will see why PH wants a NASDAQ listing , as shareholders with low testosterone line up to sell their IMU shares at .10 because they can’t endure the emotional pain of worrying that the share price might fall to .093 cents. Unbearable pain really!

For the rest of us, it’s time to relax, as the world class team at IMU finish the job off over next 5 months.